Growth Hormone Assay-Adjusted Standardization Reveals Distinct Clinical Phenotypes in Acromegaly.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Biagetti Betina, Marques Pedro, Ferrer Roser, Cardoso Luís Miguel, Moreno Eva Venegas, Fajardo-Montañana Carmen, Gonzalez-Fernandez Laura, Pérez Pena Marta María, García-Centeno Rogelio, Lozano-Aida Claudia, Novoa-Testa Iría, Pascual-Corrales Eider, Sánchón Raúl, Guerrero-Pérez Fernando, Rodríguez Rosario Oliva, Jiménez Beatriz Rodríguez, Ollero García María Dolores, Echarri Ana Irigaray, Simó-Servat Andreu, Moure Rodríguez María Dolores, Calatayud María, Villar-Taibo Rocío, Tenorio-Jimenéz Carmen, Novo-Rodríguez Cristina, Molero Inmaculada González, Iglesias Pedro, Blanco Concepción, Vidal-Ostos De Lara Fernando, Aulinas Anna, Asla Roca Queralt, Paja Miguel, Abellán Galiana Pablo, Cordido Fernando, Menéndez Torre Edelmiro, Cámara Rosa, Sarria-Estrada Silvana, Aznar Rodríguez Silvia, Lamas Cristina, Alvarez-Escola Cristina, Bernabéu Ignacio, Hanzu Felicia, Marazuela Mónica, Puig-Domingo Manel, Araujo-Castro Marta
Аннотация
METHODS: This was a multicenter cross-sectional analysis of 416 patients diagnosed with acromegaly from 2010 onward. Patients were stratified according to baseline serum GH levels standardized to the assay-specific upper limit of normal (GHxULN) using a binary classification (GH-B: <1.0×ULN vs ≥1.0×ULN) and a four-tier classification (GH-4: <0.25, 0.25-0.99, 1.0-9.9, ≥10×ULN). Unsupervised cluster analysis included age, GHxULN, insulin-like growth factor 1 (IGF-1)xULN, tumor diameter, and T2-weighted signal intensity.
RESULTS: Overall, 36% of patients had GH levels within the normal reference range for their assay (GH-B <1.0×ULN). Microadenomas (23.1%) were more frequent in older patients and associated with lower GH/IGF-1 levels. Across GH-4 categories, significant gradients were observed for age (z = -5.34, P < .001), tumor size (z = 8.01, P < .001), IGF-1 (z = 9.00, P < .001), and symptom duration (z = 4.34, P < .001). Higher GH categories were associated with greater odds of arthropathy (odds ratio 3.5, P = .015 for 1.0-9.9×ULN and odds ratio 6.58, P = .002 for ≥10×ULN). Cluster analysis revealed 3 phenotypes: cluster 1 (49.0%) [older age, lower GH/IGF-1, intermediate tumor size]; cluster 2 (44.4%) [intermediate age, moderate biochemical activity, smaller tumors]; cluster 3 (6.6%) [younger age, markedly elevated GH/IGF-1, large aggressive tumors].
CONCLUSION: GH standardization to assay-specific ULN reveals clinically meaningful phenotypes in acromegaly that correlate with age, tumor characteristics, and disease severity (particularly arthropathy). GHxULN complements IGF-1 by capturing tumor secretory activity, and this stratification approach may support more individualized clinical decision-making.